The vaccine candidate, mRNA-1273, encodes a full-length, prefusion-stabilized spike (S) protein of #SARSCoV2 complexed with lipid nanoparticles (LNPs). The Phase 1 results suggest it is "generally safe and well tolerated". Caveats: a press release, not a peer-reviewed paper.(2/3)

— David R. Liu (@davidrliu) May 18, 2020